FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2350984935> ?p ?o ?g. }

• W2350984935 endingPage "v1" @default.
• W2350984935 startingPage "v1" @default.
• W2350984935 abstract "ABSTRACT Aim: A phase III randomized, double-blinded, placebo (PLC)-controlled study of sorafenib (S) in combination with capecitabine (C) was conducted in patients with HER2-negative, locally advanced or metastatic breast cancer. The primary endpoint was progression-free survival (PFS) per independent review. Secondary endpoints included overall survival (OS), time to progression (TTP), objective response rate (ORR), disease control rate (DCR) and safety. Methods: Patients resistant to prior taxane and resistant to prior anthracycline or for whom further anthracycline was not indicated, and having received no more than one prior regimen for advanced disease were randomized 1:1 to PLC or S (600 mg daily, po, 21-day schedule) in combination with C (1000 mg/m2, bid, po, 14/7 days on/off). Results: A total of 537 patients were randomized: 266 to S + C and 271 to PLC + C. The two arms were generally well balanced; median age 54 years; 69% hormone receptor positive and 31% triple negative; and 43%/57% having received 0/1 prior lines of chemotherapy for metastatic disease. Median PFS was 5.5 mo for S + C and 5.4 mo for PLC + C; HR 0.973 (95% CI: 0.779, 1.217; one-sided p-value = 0.406). Median OS was 18.9 mo for S + C and 20.3 mo for PLC + C; HR 1.195 (95% CI: 0.943, 1.513; one-sided p-value = 0.930). There were no differences in TTP, ORR or DCR. The incidence of grade 3 AEs was 58.5% vs 39.3%, grade 4 AEs 5.8% vs 4.5%, and grade 5 AEs 6.2% vs 4.5%, S + C vs PLC + C arms, respectively. The most commonly reported grade 3 AEs included palmar-plantar erythrodysesthesia syndrome (16% vs 8%), hypertension (14% vs 2%), fatigue (7% vs 3%) diarrhea (4% vs 6%), neutropenia (4% vs 5%), and anemia (5% vs 2%). The average daily dose for C was 1734 mg/m2 vs 1914 mg/m2 with a median duration of 18 wks vs 23 wks for C in S + C and PLC + C arms, respectively. There was one drug-related grade 5 AE (hepatic failure) reported in the S + C arm. Conclusions: S + C did not improve PFS compared to PLC + C for patients with HER2-negative, locally advanced or metastatic breast cancer. The types of AEs observed were consistent with the known safety profiles of S and C. There was a trend toward worse OS in the S + C arm that is not readily explained by study treatment-related toxicity. Disclosure: P. Gomez: Honoraria: Bayer; B. Melichar: Honoraria: Bayer, Roche; J. Bergh: Clinical research: Bayer, Amgen, Astra-Zeneca, Merck, Pfizer, Roche and Sanofi-Aventis; P. Maeda, L. Huang and J. Zhang: Employment: Bayer HealthCare Pharmaceuticals. All other authors have declared no conflicts of interest." @default.
• W2350984935 created "2016-06-24" @default.
• W2350984935 creator A5004300577 @default.
• W2350984935 creator A5005769474 @default.
• W2350984935 creator A5008767871 @default.
• W2350984935 creator A5009523282 @default.
• W2350984935 creator A5015896808 @default.
• W2350984935 creator A5018118709 @default.
• W2350984935 creator A5018922989 @default.
• W2350984935 creator A5029590188 @default.
• W2350984935 creator A5031964084 @default.
• W2350984935 creator A5034290129 @default.
• W2350984935 creator A5036350616 @default.
• W2350984935 creator A5040688569 @default.
• W2350984935 creator A5043177871 @default.
• W2350984935 creator A5049977077 @default.
• W2350984935 creator A5052648400 @default.
• W2350984935 creator A5062996283 @default.
• W2350984935 creator A5073714778 @default.
• W2350984935 creator A5075498749 @default.
• W2350984935 creator A5085028425 @default.
• W2350984935 date "2014-09-01" @default.
• W2350984935 modified "2023-10-18" @default.
• W2350984935 title "A Phase III Randomized, Double-Blind, Trial Comparing Sorafenib Plus Capecitabine Versus Placebo Plus Capecitabine in the Treatment of Locally Advanced or Metastatic Her2-Negative Breast Cancer (Resilience)" @default.
• W2350984935 doi "https://doi.org/10.1093/annonc/mdu438.5" @default.
• W2350984935 hasPublicationYear "2014" @default.
• W2350984935 type Work @default.
• W2350984935 sameAs 2350984935 @default.
• W2350984935 citedByCount "13" @default.
• W2350984935 countsByYear W23509849352015 @default.
• W2350984935 countsByYear W23509849352016 @default.
• W2350984935 countsByYear W23509849352017 @default.
• W2350984935 countsByYear W23509849352018 @default.
• W2350984935 countsByYear W23509849352019 @default.
• W2350984935 countsByYear W23509849352023 @default.
• W2350984935 crossrefType "journal-article" @default.
• W2350984935 hasAuthorship W2350984935A5004300577 @default.
• W2350984935 hasAuthorship W2350984935A5005769474 @default.
• W2350984935 hasAuthorship W2350984935A5008767871 @default.
• W2350984935 hasAuthorship W2350984935A5009523282 @default.
• W2350984935 hasAuthorship W2350984935A5015896808 @default.
• W2350984935 hasAuthorship W2350984935A5018118709 @default.
• W2350984935 hasAuthorship W2350984935A5018922989 @default.
• W2350984935 hasAuthorship W2350984935A5029590188 @default.
• W2350984935 hasAuthorship W2350984935A5031964084 @default.
• W2350984935 hasAuthorship W2350984935A5034290129 @default.
• W2350984935 hasAuthorship W2350984935A5036350616 @default.
• W2350984935 hasAuthorship W2350984935A5040688569 @default.
• W2350984935 hasAuthorship W2350984935A5043177871 @default.
• W2350984935 hasAuthorship W2350984935A5049977077 @default.
• W2350984935 hasAuthorship W2350984935A5052648400 @default.
• W2350984935 hasAuthorship W2350984935A5062996283 @default.
• W2350984935 hasAuthorship W2350984935A5073714778 @default.
• W2350984935 hasAuthorship W2350984935A5075498749 @default.
• W2350984935 hasAuthorship W2350984935A5085028425 @default.
• W2350984935 hasBestOaLocation W23509849351 @default.
• W2350984935 hasConcept C121608353 @default.
• W2350984935 hasConcept C126322002 @default.
• W2350984935 hasConcept C142724271 @default.
• W2350984935 hasConcept C143998085 @default.
• W2350984935 hasConcept C204787440 @default.
• W2350984935 hasConcept C27081682 @default.
• W2350984935 hasConcept C2775930923 @default.
• W2350984935 hasConcept C2777909004 @default.
• W2350984935 hasConcept C2778019345 @default.
• W2350984935 hasConcept C2778695046 @default.
• W2350984935 hasConcept C2910363380 @default.
• W2350984935 hasConcept C526805850 @default.
• W2350984935 hasConcept C530470458 @default.
• W2350984935 hasConcept C71924100 @default.
• W2350984935 hasConceptScore W2350984935C121608353 @default.
• W2350984935 hasConceptScore W2350984935C126322002 @default.
• W2350984935 hasConceptScore W2350984935C142724271 @default.
• W2350984935 hasConceptScore W2350984935C143998085 @default.
• W2350984935 hasConceptScore W2350984935C204787440 @default.
• W2350984935 hasConceptScore W2350984935C27081682 @default.
• W2350984935 hasConceptScore W2350984935C2775930923 @default.
• W2350984935 hasConceptScore W2350984935C2777909004 @default.
• W2350984935 hasConceptScore W2350984935C2778019345 @default.
• W2350984935 hasConceptScore W2350984935C2778695046 @default.
• W2350984935 hasConceptScore W2350984935C2910363380 @default.
• W2350984935 hasConceptScore W2350984935C526805850 @default.
• W2350984935 hasConceptScore W2350984935C530470458 @default.
• W2350984935 hasConceptScore W2350984935C71924100 @default.
• W2350984935 hasLocation W23509849351 @default.
• W2350984935 hasOpenAccess W2350984935 @default.
• W2350984935 hasPrimaryLocation W23509849351 @default.
• W2350984935 hasRelatedWork W2090815170 @default.
• W2350984935 hasRelatedWork W2334893634 @default.
• W2350984935 hasRelatedWork W2570066652 @default.
• W2350984935 hasRelatedWork W2602911552 @default.
• W2350984935 hasRelatedWork W2766548167 @default.
• W2350984935 hasRelatedWork W2978733037 @default.
• W2350984935 hasRelatedWork W4361882135 @default.
• W2350984935 hasRelatedWork W4361904628 @default.
• W2350984935 hasRelatedWork W4361904941 @default.
• W2350984935 hasRelatedWork W2740739268 @default.
• W2350984935 hasVolume "25" @default.

• next